144 - Janux Therapeutics, Inc. (0001817713) (Subject)

144 - Janux Therapeutics, Inc. (0001817713) (Subject)

144 - Janux Therapeutics, Inc. (0001817713) (Subject)

144 - Janux Therapeutics, Inc. (0001817713) (Subject)

144 - Janux Therapeutics, Inc. (0001817713) (Subject)

144 - Janux Therapeutics, Inc. (0001817713) (Subject)

144 - Janux Therapeutics, Inc. (0001817713) (Subject)

144 - Janux Therapeutics, Inc. (0001817713) (Subject)

144/A - Janux Therapeutics, Inc. (0001817713) (Subject)

144 - Janux Therapeutics, Inc. (0001817713) (Subject)

Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

The company announced the appointment of Eric Dobmeier and Natasha Hernday to its Board of Directors.

GeneDx Holdings Corp. (NASDAQ:WGS) has made the biggest gains on the Russell 2000 Index in 2024 as the biotechnology company moves toward more comprehensive genetic testing. The Maryland-based company’s shares have soared 1,101% so far this year as of midday Thursday, according to Tradingview. Goldman Sachs analyst Matthew Sykes attributes much of GeneDX’s positive momentum to shifting its testing. The company went from panel-based tests, which look for variants in more than one gene, to exome/genome testing, which analyzes the bulk of a person’s DNA to find genetic variations. Also Read: GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance “We remain o

U.S. stocks were mostly higher, with the Dow Jones index gaining around 550 points on Tuesday. Shares of UnitedHealth Group Incorporated (NYSE:UNH) rose sharply during Tuesday's session following a second-quarter earnings beat. The company reported adjusted EPS of $6.80, up from $6.14 a year ago, beating the consensus of $6.66, according to data from Benzinga Pro. UnitedHealth’s revenues increased nearly $6 billion (+6.4% Y/Y) to $98.86 billion, beating the consensus of $98.34 billion, led by expansion in people served domestically at Optum and UnitedHealthcare. UnitedHealth Group shares gained 5.7% to $544.96 on Tuesday. Here are some other big stocks recording gains in today’s

U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday. Shares of Ambarella, Inc. (NASDAQ:AMBA) rose sharply during Friday's session following strong first-quarter earnings and upbeat second-quarter guidance. Ambarella posted adjusted loss of 26 cents per share, compared to market estimates for a loss of 31 cents per share. The company's quarterly sales came in at $54.473 million beating expectations of $53.875 million, according to data from Benzinga Pro. Ambarella shares jumped 23% to $59.42 on Friday. Here are some other big stocks recording gains in today's session. Latam Logistic Properties, S.A. (NYSE:LPA) shares jumped 79.5% to $464.77. The Ga

Throughout the last three months, 9 analysts have evaluated Janux Therapeutics (NASDAQ:JANX), offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 3 1 0 0 Last 30D 0 0 1 0 0 1M Ago 1 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 3 1 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $68.22, a high estimate of $100.00, and a lo

Scotiabank analyst George Farmer initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Sector Perform rating and announces Price Target of $47.

In the preceding three months, 9 analysts have released ratings for Janux Therapeutics (NASDAQ:JANX), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 4 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 2 0 0 0 2M Ago 1 1 0 0 0 3M Ago 2 1 0 0 0 Analysts have set 12-month price targets for Janux Therapeutics, revealing an average target of $68.89, a high estimate of $100.00, and a low estimate of $48.00. Witnessing a positive shift, the current a

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and raises the price target from $50 to $63.

Cantor Fitzgerald analyst Josh Schimmer reiterates Janux Therapeutics (NASDAQ:JANX) with a Overweight and maintains $100 price target.

Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024 Appointed Eric Dobmeier and Natasha Hernday to the Board of Directors Received $7.5 million development milestone payment from Merck $646.3 million in cash and cash equivalents and short-term investments at end of second quarter 2024 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Imm

The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board member Ronald W. Barrett, Ph.D., as Chairperson Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to so

USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 bil

Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024 $651.8 million in cash and cash equivalents and short-term investments at end of first quarter 2024 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2024 and provi

Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and for EGFR-TRACTr JANX008 in solid tumors Enrollment ongoing for JANX007 and JANX008 Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024 $344.0 million in year-end cash, cash equivalents, and short-term investments In March, further strengthened balance sheet with approximately $320.2 million net proceeds from underwritten offering Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the pricing of an underwritten public offering of 4,440,851 shares of its common stock at a public offering price of $46.50 per share and pre-funded warrants to purchase 1,935,483 shares of common stock at a price of $46.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate g

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it has commenced an underwritten public offering of $175.0 million of shares of its common stock. In addition, Janux expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares to be sold in the offering are to be sold by Janux.

Emerging JANX007 data illustrate a potential best-in-class profile: promising efficacy with favorable safety profile in heavily pretreated subjects with late-stage mCRPC 83% (5/6) of subjects achieved PSA50 declines with first step dose ≥ 0.2mg 56% (10/18) of subjects achieved PSA50 declines with first dose ≥ 0.1mg No CRS greater than Grade 2 was observed in any cohort Early JANX008 data display differentiated safety and encouraging signs of efficacy in heavily pretreated subjects with different solid tumor types A subject with NSCLC achieved a RECIST PR maintained through 18-weeks with 100% target lung lesion reduction and elimination of liver metastasis with no CRS or TR

The virtual event will take place on Monday, February 26th, 2024, at 4:30PM ET Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced it will host a virtual event discussing updated clinical data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 on Monday, February 26th, 2024, at 4:30PM ET. David Campbell, Ph.D., President & Chief Executive Officer will discuss interim clinical updates for JANX007, a TRACTr that targets prostate-specific membrane